Endostatin
Endostatin is a potent anti-angiogenic protein released by proteolytic processing of the C-terminal domain of collagen alpha-1(XVIII), encoded by the COL18A1 gene. It inhibits endothelial cell proliferation and migration, and the gene has the aliases KS, KNO1 and KNO. Browse Assay Genie's current range of Endostatin research reagents below, or read on for the biology behind the target.
Endostatin potently inhibits endothelial cell proliferation and angiogenesis. It is thought to act in part by binding heparan sulfate proteoglycans involved in growth factor signalling. It inhibits VEGFA-induced endothelial cell proliferation and migration, and appears to restrain VEGFA-mediated signalling by blocking the interaction of VEGFA with its receptor KDR/VEGFR2. It also modulates endothelial cell migration in an integrin-dependent manner, involving integrin ITGA5:ITGB1 and, to a lesser extent, ITGAV:ITGB3 and ITGAV:ITGB5.
Endostatin is not produced from a gene of its own. The COL18A1 gene encodes the alpha chain of type XVIII collagen, one of the multiplexins: extracellular matrix proteins with several triple-helix collagenous domains interrupted by non-collagenous domains. Proteolytic processing at several endogenous cleavage sites in the C-terminal domain releases endostatin, which can inhibit angiogenesis and tumour growth. The precursor is secreted into the extracellular matrix, including the basement membrane. A long isoform carries an N-terminal domain homologous to the extracellular part of frizzled receptors, and alternative splicing yields multiple transcript variants. The mouse ortholog is Col18a1.
The gene was previously named collagen, type XVIII, alpha 1, and also Knobloch syndrome, type 1, because mutations in it are associated with Knobloch syndrome. The main features of this syndrome are retinal abnormalities, so type XVIII collagen may play an important role in retinal structure and in neural tube closure. HGNC places the gene in the multiplexin collagens group and also among microRNA protein coding host genes.
Endostatin potently inhibits endothelial cell proliferation and angiogenesis, making it a central molecule for studying how new vessel growth is restrained.
It inhibits VEGFA-induced endothelial responses, apparently by blocking VEGFA binding to KDR/VEGFR2, so it is used to probe this signalling axis.
As a potent antiangiogenic fragment able to inhibit tumour growth, endostatin is relevant to studies of how angiogenesis supports cancer progression.
COL18A1 mutations are associated with Knobloch syndrome, linking type XVIII collagen to retinal structure, neural tube closure and basement membrane biology.
Endostatin potently inhibits endothelial cell proliferation and angiogenesis. It inhibits VEGFA-induced endothelial proliferation and migration, seems to block VEGFA binding to KDR/VEGFR2, and modulates endothelial migration in an integrin-dependent manner, mainly through ITGA5:ITGB1.
Endostatin is not encoded separately. The COL18A1 gene encodes the alpha chain of type XVIII collagen, and proteolytic cleavage at several sites in its C-terminal domain produces endostatin. Alternative splicing gives multiple transcript variants, including a long isoform with a frizzled-like N-terminal domain.
Yes. Mutations in COL18A1 are associated with Knobloch syndrome, whose main features are retinal abnormalities. This suggests type XVIII collagen contributes to retinal structure and neural tube closure. The mouse ortholog is Col18a1; check the datasheet of any product for its validated reactivity.
Other collagens, including the related multiplexin collagen COL15A1 and basement membrane collagens, with products at Assay Genie.
Gene and protein annotations from HGNC, NCBI Gene and UniProt P39060; product specifications from Assay Genie datasheets.